Fractyl Health Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
46.2%projected annual EPS growth
Analyst Coverage
6analysts covering
FY EPS (est.)
-$0.39next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| REMAIN-1 Pivotal Cohort Topline 6-Month Randomized Data Readout | 15 Oct 2026 |
Monitoring Framework
Key Performance Indicators
REMAIN-1 Pivotal Cohort Randomization Status Quarterly100.0Target: 100% Complete
Cash Runway (Years) Quarterly0.5Target: Extend beyond early 2027
Watch Items
- REMAIN-1 Pivotal Cohort 6-Month Topline DataTrigger: Statistically significant post-GLP-1 weight maintenance compared to shamAction: Prepare and submit FDA De Novo marketing application
- RJVA-001 Phase 1/2 First-in-Human Trial DosingTrigger: First patient dosed in the NetherlandsAction: Initiate safety monitoring and prepare for preliminary data readout
Research as of 20 Jun 2026